ADCETRIS Reimbursement Status
ADCETRIS Resources and Videos
ADCETRIS prescribing information and adverse event reporting
ADCETRIS (brentuximab vedotin) has received a conditional marketing authorisation in Europe
C-APROM/UKI/ADCE/0020 November 2020
1ADCETRIS Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2859/smpc
This virtual stand was produced and fully funded by Takeda UK Ltd and is intended for healthcare professionals only.
© Takeda UK Limited, 2020. Registered office: 1 Kingdom Street, London, W2 6BD, United Kingdom. Registered in England and Wales No. 3362860